What is actually happening in Long COVID?

How Many People Are Still Ill from COVID?

An estimated 1.5 million people in the UK have long COVID, down from a peak of 2.1 million in 2022. 800,000 report limitations on daily activities. 50,000 are unable to work. The estimated economic cost is £5 billion a year.

Long COVID — defined by NICE as symptoms persisting four or more weeks after infection — peaked at 2.1 million sufferers across Great Britain in January 2022, with subsequent estimates putting the figure at approximately 1.5 million in 2024.[1] Women are affected more than men, and prevalence concentrates heavily among working-age adults aged 35–69. Some 800,000 people report long COVID limits their daily activities; 50,000 are unable to work at all.[1] OBR estimates attribute roughly 20% of the rise in long-term sickness inactivity (from 2.1 million to 3.2 million since 2019) to long COVID, with the estimated economic cost running to £5 billion per year.[2] NHS England established 85 long COVID assessment clinics with a 12-week average wait; there is no licensed treatment, with care symptom-based.[3] Vaccination reduces long COVID risk by around 50%, and the NIHR funded over £50 million of research through the PHOSP-COVID study.[4]

Healthcare workers, care home staff, and transport workers unable to work from home were disproportionately affected during the first two waves before vaccination — mirroring pandemic exposure patterns. Post-exertional malaise, where physical or cognitive effort triggers symptom relapse lasting days, makes conventional rehabilitation counterproductive and traps patients in enforced inactivity. Children were not spared: multisystem inflammatory syndrome (MIS-C and PIMS-TS) hospitalised hundreds, with some experiencing lasting cardiac and neurological effects. Clinical trials in 2024–25 are testing antivirals, low-dose naltrexone for neuroinflammation, and apheresis, though none has yet produced definitive results.

People with long COVID (estimated)

1.5M

2024 · Down from 2.1M peak (2022) · 800K with daily limitations · 50K unable to work

View chart →

NHS Long COVID clinics

85

2024 · Down from 91 peak · 12-week average wait · 91 clinics at peak in 2022-23

View chart →

Estimated economic cost

£5bn

2024 · Down from £5.7bn peak · Lost output from work absence · Still one of UK's largest pandemic legacies

View chart →

Most common long COVID symptoms, 2023

Percentage of long COVID sufferers reporting each symptom.

Source: ONS — COVID Infection Survey 2023. Multiple symptoms per person.

Long COVID prevalence, Great Britain, 2021–2024

Estimated number of people self-reporting symptoms 4+ weeks after COVID-19 infection. Peaked at 2.1 million in 2022. Declining as population immunity grows but remaining substantial.

Estimated economic cost of long COVID, UK, 2021–2024

Estimated annual output loss from long COVID-related work absence and reduced productivity (£bn). Peaked at £5.7bn in 2023 and is declining slowly as prevalence falls.

What's improving

–29%long COVID prevalence falling from 2.1M to 1.5M since 2022 peak

Long COVID prevalence has fallen by around 29% from its 2022 peak, driven by growing immunity (prior infection plus vaccination) and changes in circulating variants. Vaccination reduces long COVID risk by an estimated 50%. NIHR has funded £50M+ of research including the PHOSP-COVID study which is tracking long-term recovery. NICE guidelines (NG188) have standardised care. Multiple clinical trials of potential treatments were ongoing in 2024, targeting fatigue, cognitive symptoms, and autonomic dysfunction.

Source: ONS — COVID Infection Survey; NHS England — Long COVID assessment services 2024.

  1. [1]ONSCOVID Infection Survey — long COVID prevalence estimates, 2024
  2. [2]OBREconomic and fiscal outlook — long-term sickness inactivity, 2024
  3. [3]NHS EnglandLong COVID assessment clinics data, 2024
  4. [4]NIHRPHOSP-COVID study — long COVID research funding, 2024

Sources & Methodology

Methodology

Known issues

    More in NHS & Healthcare